Ongoing Clinical Trials for Schizoaffective Disorder
There are currently 2 ongoing clinical trials studying treatments for schizoaffective disorder. These trials are investigating the effectiveness of different medication approaches, including intensified treatment combinations and the genetic factors that influence how patients respond to antipsychotic medications. The trials are being conducted across several European countries, including Austria, Czechia, Germany, Italy, and Spain.
Clinical trial locations
- Austria
- Czechia
- Germany
- Italy
- Spain
Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure
This trial is being conducted in Germany, Austria, Italy, and Spain and focuses on patients who have not responded well to their first medication treatment. The study aims to help people with schizophrenia, schizoaffective disorder, or schizophreniform disorder by exploring whether an intensified treatment approach over six weeks can be more effective than standard treatment methods.
Main inclusion criteria:
- You must be between 18 and 70 years old and able to provide written consent to participate
- You must have a confirmed diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- You must be experiencing a first-time treatment failure, meaning your initial medication has not worked effectively after at least 4 weeks of use
- Your symptoms must be at a certain level of severity and causing difficulties in daily functioning, as measured by specific assessment scales
- Women of childbearing potential must use effective birth control during the study and have a negative pregnancy test at the start
Main exclusion criteria:
- Patients who do not have a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Patients who have not experienced a first-time treatment failure
- Patients who are not within the specified age range or are not willing or able to follow study procedures
- Patients who belong to vulnerable populations not included in the study design
Focus of the trial: The study compares an intensified medication treatment with usual treatment methods over a six-week period. Participants will have regular visits to monitor their progress, and researchers will assess changes in symptom severity using the Positive and Negative Syndrome Scale (PANSS). The study also examines other aspects such as anxiety, depression, quality of life, and any side effects experienced during treatment.
Investigational drugs: The trial uses an intensified pharmacological treatment approach that includes a combination of medications such as clozapine, ziprasidone, amisulpride, aripiprazole, risperidone, paliperidone, and other antipsychotic medications. The specific combination and dosage are carefully selected and monitored by healthcare professionals throughout the six-week treatment period.
Study on the Safety and Effectiveness of Olanzapine for Patients with Schizophrenia
This trial is taking place in Czechia and focuses on understanding how genetic factors affect the way patients respond to olanzapine treatment. The study aims to provide insights into personalized treatment approaches by examining specific gene variations that may influence treatment effectiveness.
Main inclusion criteria:
- You must be between 18 and 60 years old
- You must have a diagnosis of schizophrenia or schizoaffective disorder according to the ICD-10 classification system
- You must be currently receiving or planning to start treatment with olanzapine
- You must be willing to participate and provide informed consent
- Women of childbearing potential must use at least one effective method of birth control
Main exclusion criteria:
- Patients with a history of psychoses other than those specified in the inclusion criteria
Focus of the trial: The study examines the frequency of certain gene variations in genes like CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4, which may influence how patients respond to olanzapine. Researchers will monitor changes in symptoms using the PANSS scale and track how quickly participants respond to treatment. The study also evaluates any side effects and aims to understand how individual genetic differences affect treatment outcomes.
Investigational drug: Olanzapine is taken orally as a film-coated tablet and works by balancing certain chemicals in the brain, which can improve mood, thoughts, and behavior. The medication blocks specific receptors in the brain, such as dopamine and serotonin receptors, helping to reduce symptoms of psychosis. This study specifically examines how genetic and epigenetic factors might affect how well olanzapine works for different individuals.
Summary
These two ongoing clinical trials represent different approaches to understanding and treating schizoaffective disorder and related conditions. The first trial, conducted across multiple countries in Europe (Germany, Austria, Italy, and Spain), focuses on patients who have not responded to initial treatment and tests whether an intensified combination of medications can provide better outcomes. The second trial, taking place in Czechia, takes a more personalized medicine approach by studying how genetic variations influence response to olanzapine treatment.
Both studies emphasize the importance of finding more effective treatment strategies for patients living with these challenging mental health conditions. The multi-country trial demonstrates a collaborative European effort to address treatment-resistant cases, while the genetic study in Czechia represents a growing interest in understanding individual differences that affect medication response. These trials may help healthcare providers develop more targeted and effective treatment approaches for patients with schizoaffective disorder in the future.